suPAR vs methylation clocks: a clinical comparison.

01What each test actually measures

A meaningful comparison has to start with the underlying biology. The two categories of test are not measuring the same thing.

Methylation clocks measure patterns of DNA methylation - the addition of methyl groups to specific cytosine bases in your DNA - at hundreds of thousands of sites across the genome. DNA methylation is a fundamental epigenetic mechanism that regulates gene expression, and its patterns shift in characteristic ways as we age. A methylation clock takes the pattern at a defined set of CpG sites, runs it through a statistical model trained on chronological age or on a clinical endpoint, and outputs an estimated biological age or pace of aging.

The first-generation clocks (Horvath 2013; Hannum 2013) were trained on chronological age. The second-generation clocks were trained on more clinically meaningful endpoints - PhenoAge (Levine 2018) on a composite of clinical biomarkers, GrimAge (Lu 2019) on time-to-death, and DunedinPACE (Belsky 2022) on a longitudinal pace-of-aging measure from the Dunedin cohort.

suPAR measures a single protein - soluble urokinase plasminogen activator receptor - circulating in your bloodstream. suPAR is released into the blood by activated immune cells and reflects the stable, chronic level of immune activation in your body. Because chronic immune activation is one of the central biological processes that drives aging across multiple organ systems, suPAR turns out to be a remarkably good single-number summary of long-term health risk.

The conceptual difference matters. Methylation clocks measure a signature that is associated with aging at the cellular level. suPAR measures one of the actual biological drivers of aging at the organismal level. Both are scientifically valid approaches. They differ in how directly they link to the biology that affects healthspan and lifespan.

02Regulatory status: clinical assay vs wellness product

This is the difference that the consumer market obscures most consistently.

The suPAR assay is a CE-IVD certified in vitro diagnostic biomarker. It has been used in hospital emergency departments across Europe for over a decade as part of standard clinical practice. It is regulated as a clinical instrument, with documented analytical performance specifications and clinical validation in published trials.

Most methylation-based biological age tests are not. They are wellness products - sold to consumers and clinics, but not regulated as clinical diagnostics. This does not mean they are not built on real science. It means the underlying assay does not have to meet the same documentation, quality, and validation requirements as a clinical test. Lot-to-lot consistency, analytical performance, and quality control are governed by the manufacturer's choices, not by regulatory authorities.

For a research tool, the wellness regulatory status is fine. For an instrument that you intend to use to track an individual person's healthspan trajectory over years, with clinical decisions potentially anchored to the results, the difference matters.

At Supar Health, we are explicit about the regulatory boundary. The suPAR assay is CE-IVD certified. The reporting layer that contextualizes the result against population norms and healthspan trajectory is a wellness assessment intended for use within a doctor-patient relationship. Clinical performance evaluation for IVDR certification of the reporting layer is ongoing.

03Predictive power for long-term health outcomes

The single most important question about any biological age test is: how well does it predict the outcomes that matter?

In the scientific literature, predictive power is reported as hazard ratios - the increase in risk associated with a given biomarker level, adjusted for other risk factors. A hazard ratio of 2.0 means double the risk. A hazard ratio of 3.0 means triple. A test with a hazard ratio of 1.2 is barely doing useful work.

suPAR's predictive performance

suPAR has been validated as a predictor of long-term health outcomes across many of the conditions that matter most for healthspan:

• Cardiovascular disease incidence
• Type 2 diabetes incidence
• Chronic kidney disease progression
• Cancer outcomes across multiple cancer types
• Cognitive decline and dementia incidence
• Frailty and mobility decline
• All-cause long-term outcomes

In each of these domains, suPAR shows hazard ratios that are independent of conventional risk factors (CRP, age, sex, smoking status, lipid levels, blood pressure) and frequently in the range of 2–3× or higher between high and low suPAR groups in published cohort studies.

Methylation clock predictive performance

First-generation clocks (Horvath, Hannum) trained on chronological age have shown modest predictive power for clinical outcomes. They are excellent for what they were designed to do - estimate chronological age from methylation - but predicting clinical events was not their primary objective.

Second-generation clocks (PhenoAge, GrimAge, DunedinPACE) were designed with clinical outcomes in mind and perform substantially better. GrimAge in particular has shown strong hazard ratios for mortality in multiple cohorts.

Where we land: across the published morbidity hazard ratio literature, suPAR shows the highest morbidity hazard ratios of any biological age test studied. Our dedicated comparison analysis with specific cited figures by outcome is forthcoming on the comparison page.

04Test-retest reliability: the quiet problem in methylation

This is the issue that has received increasing attention in the methylation literature itself, and that most consumer-facing methylation products do not discuss in their marketing.

Test-retest reliability is the answer to a simple question: if you measure the same person twice in close succession (when nothing about their underlying biology has changed), how similar are the two results?

For a tracking instrument, this is crucial. If a methylation clock tells you that your biological age dropped by two years after six months of intervention, you want to know how much of that change is real and how much is measurement noise.

The methylation field has been refreshingly honest about this. Higgins-Chen et al., writing in Nature Aging in 2022, explicitly addressed the reliability issue and proposed principal-component-based methodologies to address it. Their analysis demonstrated that first-generation epigenetic clocks have substantial measurement noise at the individual level - useful at the population scale, but limited at the individual scale.

DunedinPACE was designed with improved reliability in mind, and is currently the most reliable of the methylation pace measures. But measurement-noise considerations remain real across the methylation category.

Single-analyte immunoassays like suPAR have a different reliability profile. The measurement is direct (a single protein concentration), the assay is clinically validated to documented performance specifications, and the longitudinal behavior is well-characterized in the literature. The intra-assay coefficient of variation is among the lowest of any biomarker in the biological age category.

For individual longitudinal tracking - which is what most consumers and clinicians want - the reliability advantage matters.

05Responsiveness: can the test detect when you actually change?

The question that almost no biological age product wants to answer directly in marketing.

If you genuinely improve your sleep, cut alcohol, exercise consistently, lose visceral fat, and stop smoking over the course of a year - does the test register the change?

For first-generation methylation clocks: the response is limited. Several lifestyle intervention studies have shown minimal or inconsistent changes in Horvath or Hannum biological age in response to even substantial behavioral or pharmacological interventions.

For second-generation methylation clocks: the response is better but still modest. The most notable result is from the CALERIE trial (Waziry et al., Nature Aging, 2023), which showed that DunedinPACE - the pace-of-aging measure - slowed measurably in participants on a sustained caloric restriction protocol over two years. That is a meaningful result. But it is a single study of a heroic intervention, and the magnitude of the effect was modest.

For suPAR: responsiveness to lifestyle intervention is well-established across many published studies and many intervention types. Smoking cessation reduces suPAR within months. Weight loss reduces suPAR in proportion to fat mass lost. Exercise interventions reduce suPAR. Dietary improvement reduces suPAR. Alcohol cessation reduces suPAR.

The reason for this difference, mechanistically, is straightforward. suPAR is a marker of the very biological processes (chronic immune activation) that the major lifestyle drivers of aging affect. When you remove the upstream driver, the downstream marker responds. Methylation patterns shift more slowly and less consistently in response to behavioral inputs.

For someone whose primary use case is tracking their own intervention success, this is the practical difference that matters most.

06Clinical evidence base

A test's evidence base is not just credentialing - it reflects how thoroughly the scientific community has been able to interrogate, refine, and validate the biomarker over time.

suPAR: over 1,250 published clinical studies (PubMed, May 2026). Over one million tests performed in clinical settings worldwide as of January 2024. Over twenty years of hospital and emergency department use.

Methylation clocks: the foundational research base is strong - the Horvath and Hannum papers are among the most-cited in the aging field. Second-generation clocks have a growing literature, with GrimAge and DunedinPACE in particular accumulating substantial supporting evidence. But the overall published clinical literature for any single methylation clock product is substantially smaller than for suPAR.

Glycan age: approximately 100 publications. A smaller but legitimate evidence base.

Volume of publication is not, in itself, proof of clinical value. But it is a reasonable proxy for how thoroughly a biomarker has been examined under diverse conditions, in diverse populations, for diverse outcomes. For a clinician evaluating which biomarker to integrate into their practice, the size of the evidence base matters.

07Turnaround time

A practical but important difference. Most methylation tests require array-based laboratory processing and have turnaround times of three to six weeks. suPAR is a clinical immunoassay with turnaround times measured in days.

For serial testing protocols - which is the appropriate clinical use of any biological age test - fast turnaround supports tighter intervention cycles and more responsive patient engagement.

08Where methylation tests are the right choice

We want to be honest about where the methylation field has advantages.

For research into the cellular mechanisms of aging, methylation arrays are irreplaceable. They measure a fundamental epigenetic process at a level of granularity that no single biomarker can match. If you are a researcher studying aging biology, methylation testing is part of your toolkit.

For breadth of biological signal, methylation arrays measure over 800,000 sites simultaneously. That breadth captures information about many dimensions of biological state - different methylation clocks within the same array can give different angles on the same person's biology.

For users who want a research-style dashboard with multiple aging-related outputs, multi-clock products (such as TruDiagnostic's offerings) provide a richer set of derived metrics than any single-biomarker test.

For pace-of-aging measurement as a conceptually distinct readout from snapshot age, DunedinPACE remains a uniquely interesting measure that has no direct equivalent in the single-biomarker space.

09Where suPAR is the right choice

For most users tracking their own healthspan trajectory, and for most clinical practices integrating biological age testing into patient care, suPAR is the more honest and useful tool. The advantages aggregate:

• Clinical regulatory status with full CE-IVD certification
• Highest published morbidity hazard ratios in the biological age category
• High individual-level test-retest reliability
• Well-documented responsiveness to lifestyle intervention in weeks to months
• Fast turnaround supporting tight serial-testing cadences
• Over 1,250 published clinical studies
• A clinical heritage of over twenty years in hospital use
• A single, interpretable number - no dashboard required

These are not marginal advantages. Each one would, individually, be a meaningful argument for the test. Taken together, they describe a categorically different instrument from a methylation clock.

10The bottom line

If your goal is to study cellular aging mechanisms in research, methylation arrays are the right tool. If you want a wellness-grade snapshot of your epigenetic state, second-generation methylation clocks like GrimAge and DunedinPACE are reasonable choices.

If your goal is to track and prove your healthspan trajectory using the most clinically grounded, responsive, and reliable measurement available - and to do so within a doctor-patient relationship where the result can actually inform care - suPAR is the better choice.

We built Supar Health on that conviction. The science supports it, the clinical heritage supports it, and the user experience supports it. The remaining work is making it accessible to the people who need it.